Ultimate Scholar

Pfizer headquarters, in the conference room.

A very serious meeting is going on.

Of course, although it is called a meeting, it is actually more like an interrogation.

John Yang, the president of Pfizer, was sitting in the first seat, looking straight at Skarner Slavi who was sitting opposite.

"Dr. Slavi, the company has given you a lot of resources and funding, not for the purpose of allowing you to develop this kind of drug that can't even pass the first phase of clinical trials."

John Yang's tone was very calm, but for Skarner Slavi who was sitting opposite him, it was full of pressure.

After all, it can be called the largest pharmaceutical company in the world. As the president of this kind of company, John Young is ruthless enough when he should be.

Skarner Slavi took a deep breath, calmed down his emotions, and said, "President, I admit that in this research and development, I was a little eager for quick success."

"Of course, that doesn't mean our work is a complete failure."

He regained his composure, and then said: "The main problem with PEFF is that it will lead to a higher degree of platelet activation."

"Now we only need to continue to experiment with the principle of increasing the degree of platelet activation, and then modify this principle to solve this problem and retain the original thrombolytic effect of PEFF."

"The actual thrombolytic effect of PEFF, Mr. President, you should also know how excellent it is."

John Yang smiled: "It can both dissolve thrombosis and coagulate thrombosis."

"Dr. Slavi, the drug you developed is quite ironic."

Then he "tsk" again, "Tell me, why did the problem appear in the first phase of clinical trials?"

Everyone present could hear the pity in his words.

This kind of medicine is like a planned obsolescence, and it is deeply favored by companies like them.

It's just a pity that they were unlucky, and they encountered this kind of thing in the first phase of clinical trials.

In fact, it was mainly because the patient with the problem had a relatively high degree of platelet activation, and then the impact of PEFF led to this clinical accident.

As long as the luck is a little bit better, if these clinical volunteers do not have this kind of situation, with their Pfizer influence, it will be easy for this drug to be successfully launched. At that time, even if there is another problem, they will be able to cover up similar news .

Anyway, as long as it can be listed, it can make money.

Among their other marketed drugs, there are more or less such unspecified drugs that may cause life-threatening side effects.

Finally, John Yang sat up straight, and then said to Skarner Slavi: "Well, Dr. Slavi, no matter what, you are also our chief scientist, and you have made many great contributions to the company."

"This failure can be regarded as a lesson. I also hope that, as you said just now, PEFF will be modified, and then it will reach the level where it can be listed again."

"At least, the stock price brought about by this incident has made our shareholders some money, so they don't have much dissatisfaction with you, but I still hope that you can prove your behavior next time." The competence of Pfizer's Chief Scientist."

Skarner Slavi heaved a sigh of relief, and a smile appeared on his face: "Just rest assured, I will not disappoint the directors."

For this result, he actually had expected it a long time ago. After all, he has earned so much money for the company, so it is impossible to fire him because of this incident. As for the clinical volunteer, there is nothing wrong with it. It's nothing more than a lawsuit. The last thing their company is afraid of is a lawsuit. Anyway, the clinical volunteers have signed an agreement, not to mention that these volunteers are paid, and they will only win the lawsuit.

"Okay, then today's meeting is over, let's adjourn."

John Yang made an announcement, and then he stood up first to leave, but at this moment, the door of the meeting room opened suddenly, and his assistant ran in, and then whispered a few words in his ear.

Then the people present could see that their president's complexion gradually turned sour.

No one dared to leave for a while. \b

And John Yang glanced at the people present, then sat back in his seat and said, "The meeting continues."

Then he stared at Skarner Slavi again, and said, "What's your relationship with Kingsley Weir and Li Mu?"

Skarner Slavi was taken aback for a moment, a little puzzled.

"President, why...why do you suddenly ask this question?"

"Just answer first."

"I... I'm not very familiar with Li Mu, but I invited him to join our Pfizer at the dinner of the Max Planck Society's Life Science Conference. You know about this. As for Kingsley Weir... er... "

Under the gaze of the president, Skarner Slavi could only talk about his conflict with Kingsley Weir back then.

Knowing that Skarner Slavi's girlfriend was snatched away by this man named Kingsley Weir, everyone present wanted to laugh, but they didn't dare to laugh. \b

John Yang was silent for a moment. He only knew that there was a conflict between Skarner Slavi and Kingsley Weir, but he didn't expect it to be this conflict. He didn't know what to say for a while.

But finally, he shook his head, beckoning to the assistant next to him.

Afterwards, the assistant nodded, and said to everyone: "According to the latest information, the team of Li Mu and Kingsley Weir has developed a new type of thrombolytic drug, which they named RSCA. "

"This drug has a stronger thrombolytic effect than the fourth-generation thrombolytic drugs. In addition, it can also form a film on the surface of insoluble fibrin to make it smoother, making it less likely to clot stand up."

"In addition, according to the news, the biggest advantage of their new thrombolytic drug is that it is more specific and only targets the fibrin in the thrombus, instead of dissolving blood vessels and causing bleeding symptoms."

"What?!"

Skarner Slavi's eyes widened immediately.

After hearing the news, the other researchers in the conference room couldn't sit still for a while.

"Can you develop this thrombolytic drug?"

Anyone who has done some research on thrombolytic drugs will be shocked at this time.

"And I remember that Kingsley Weir once approached us to develop this drug, but we refused to cooperate with him because of you. I still remember that you said he was a liar."

John Yang frowned gradually: "I hope you can give me an explanation for this matter!"

And Skarner Slavi was already full of disbelief: "Impossible, absolutely impossible!"

...

"Pfizer's New Drug Fails, "Cheater"'s New Drug Succeeds? "

"The most perfect thrombolytic drug, RSCA? "

"Li Mu's data analysis method reproduces the power, perfect thrombolytic drugs set off a medical revolution"

"..."

With the publication of the paper on RSCA in "Cell", the effect of RSCA immediately set off a shock in the entire medical field, even worse than Pfizer's PEFF.

After all, RSCA can be regarded as the most perfect thrombolytic drug in terms of effect alone.

In the paper, people in the biomedical field once again saw Li Mu's data analysis method, which showed a huge effect, just like the paper in the special issue of "The Lancet".

For a time, the entire medical world was shaken by the effect of RSCA.

...

Mayo Clinic, in Jason Layton's office.

As a top cardiac surgeon, he is currently being interviewed by a news reporter.

"Dr. Layton, hello."

A reporter from the "New York Times" said to Jason Layton with great respect that in this country, doctors and lawyers are the most respected professions, not to mention top doctors like Jason Layton.

"I believe that in the recent news, you should know about the failure of Pfizer's new thrombolytic drug and the most perfect thrombolytic drug developed by the mathematical genius Li Mu."

"Of course, I've seen these two news items." Jason Layton nodded.

The reporter smiled slightly and then asked: "I heard that in your operations, generally speaking, the need for thrombolytic drugs is relatively high. Is this true?"

Jason Layton laughed: "Of course, it's true."

"Thrombolytic drugs are a necessary drug for cardiac surgery, because you have to know that once you have heart surgery, it is very easy to form blood clots in the patient's body-or any surgery is prone to lead to the formation of blood clots, Because during and after the operation, the human body will be in a state of stress, and the blood will be in a hypercoagulable state, mobilizing the coagulation factors in the body, which will lead to the problem of thrombus.”

"Especially in our cardiac surgery, the problems caused by thrombus have always affected our surgery, so in our surgery, the main purpose of cardiac angiography, cardiac CT, etc. is to detect whether there is Thrombosis."

"So it is!" The reporter nodded.

"So, what do you think about Pfizer's PEFF and Li Mu's RSCA? Will RSCA succeed?"

After thinking for a while, Jason Layton said: "PEFF has nothing to say. This thrombolytic drug is really ridiculous. A thrombolytic drug that can increase the activation of platelets is like wearing pants to go to the toilet. It is extremely stupid. "

"As for RSCA... I don't know how to evaluate it at present, but if its effect is really as stated in the paper, I would say that this will be my favorite thrombolytic drug for cardiac surgeons. The thrombolysis speed is fast, the efficiency is high, and the most important thing is that there is still a two-year effect duration..."

"I would say there is no better clot-dissolving drug."

"So, next we just need to wait for the verification of clinical trials."

"Of course, psychologically, I believe it."

"Although I haven't met Li Mu with my own eyes, I feel in my heart that this is a miraculous person."

Jason Layton said with a smile.

Under the influence of Li Mu's thesis, he had developed admiration for this man he had never met.

And hearing what Jason Layton said, the reporter also felt emotional, "Yeah, he is indeed a magical person. As I said just now, he is obviously a math genius, but why is he so omnipotent?"

Jason Layton nodded approvingly.

...